Trial Profile
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; L-DOS 47 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Helix BioPharma
- 02 Oct 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2025.
- 02 Oct 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
- 16 Mar 2022 Planned End Date changed from 31 Oct 2021 to 31 Aug 2023.